Discontinued — last reported Q4 '25
Flex Ltd. Acquisitions decreased by 250.0% to -$3.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.9%, from $346.00M to -$3.00M. Over 3 years (FY 2022 to FY 2025), Acquisitions shows a downward trend with a -9.1% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $134.75M | $134.75M | $134.75M | $134.75M | -$500.00K | -$500.00K | -$500.00K | -$500.00K | $0.00 | $0.00 | $0.00 | $0.00 | -$2.00M | $3.00M | $346.00M | $58.00M | $41.00M | $2.00M | -$3.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.4% | +0.0% | +0.0% | +0.0% | +100.0% | — | — | — | — | +250.0% | >999% | -83.2% | -29.3% | -95.1% | -250.0% |
| YoY Change | — | — | — | — | -100.4% | -100.4% | -100.4% | -100.4% | +100.0% | +100.0% | +100.0% | +100.0% | — | — | — | — | >999% | -33.3% | -100.9% |